Details:
BI456906 (survodutide) is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action. It is being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Lead Product(s): Survodutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BI 456906
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
The companies will conduct a Phase 2b double-blind, placebo-controlled study to investigate the safety and efficacy of Novo Nordisk’s semaglutide and a fixed-dose combination of Gilead’s investigational FXR agonist cilofexor and investigational ACC inhibitor firsocostat.
Lead Product(s): Semaglutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 18, 2021
Details:
Novo Nordisk successfully completed the phase 2b trial with ziltivekimab in cardiovascular disease. Further, Novo Nordisk requested priority review in the US of the filing of semaglutide 2.4 mg in obesity based on a priority review voucher.
Lead Product(s): Semaglutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Rybelsus
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2020